Abstract: The present disclosure relates to immunoassay methods and immunoassay kits for determining measuring the amount of wild type huntingtin protein in a sample, e.g., a cerebral spinal fluid sample from a Huntington's disease patient, as well as methods of treating Huntington's disease patients employing such immunoassays.

Abstract: A method and apparatus for conducting specific binding assays are claimed. This invention relates to an initial non-receptor ligand interaction with nanoparticles or other solid phases followed by specific detection methods used for detecting biological, chemical or environmental entities. This invention employs an on-device ligand attachment to nanoparticles or other solid phase followed by the specific capture in discrete zones on the device. The ligand-bound complexes assemble on the ligand specific capture zone leading to a visible diagnostic result, if colored solid phases are employed.